JPWO2022067086A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022067086A5
JPWO2022067086A5 JP2023518779A JP2023518779A JPWO2022067086A5 JP WO2022067086 A5 JPWO2022067086 A5 JP WO2022067086A5 JP 2023518779 A JP2023518779 A JP 2023518779A JP 2023518779 A JP2023518779 A JP 2023518779A JP WO2022067086 A5 JPWO2022067086 A5 JP WO2022067086A5
Authority
JP
Japan
Prior art keywords
arg
phe
trp
hcys
pen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542985A (ja
JP2023542985A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052032 external-priority patent/WO2022067086A1/en
Publication of JP2023542985A publication Critical patent/JP2023542985A/ja
Publication of JP2023542985A5 publication Critical patent/JP2023542985A5/ja
Publication of JPWO2022067086A5 publication Critical patent/JPWO2022067086A5/ja
Pending legal-status Critical Current

Links

JP2023518779A 2020-09-24 2021-09-24 メラノコルチン-4受容体経路関連障害の治療方法 Pending JP2023542985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082867P 2020-09-24 2020-09-24
US63/082,867 2020-09-24
PCT/US2021/052032 WO2022067086A1 (en) 2020-09-24 2021-09-24 Methods of treating melanocortin-4 receptor pathway-associated disorders

Publications (3)

Publication Number Publication Date
JP2023542985A JP2023542985A (ja) 2023-10-12
JP2023542985A5 JP2023542985A5 (https=) 2024-10-02
JPWO2022067086A5 true JPWO2022067086A5 (https=) 2024-10-02

Family

ID=80845850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518779A Pending JP2023542985A (ja) 2020-09-24 2021-09-24 メラノコルチン-4受容体経路関連障害の治療方法

Country Status (13)

Country Link
US (1) US20240058414A1 (https=)
EP (1) EP4216979A4 (https=)
JP (1) JP2023542985A (https=)
KR (1) KR20230095956A (https=)
CN (1) CN116507353A (https=)
AR (1) AR123603A1 (https=)
AU (1) AU2021350017A1 (https=)
CA (1) CA3192873A1 (https=)
CL (1) CL2023000823A1 (https=)
CO (1) CO2022009561A2 (https=)
MX (1) MX2023003360A (https=)
TW (1) TW202228760A (https=)
WO (1) WO2022067086A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023308310A1 (en) * 2022-07-12 2025-01-16 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2025106751A1 (en) * 2023-11-14 2025-05-22 Rhythm Pharmaceuticals, Inc. Combinations of a potassium channel activator and an mc4r agonist and related methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Similar Documents

Publication Publication Date Title
US12285460B2 (en) Pharmaceutical compositions
Eaves et al. Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats
JP2021102650A5 (https=)
JP2018531937A5 (https=)
JPWO2022067086A5 (https=)
CN108697758B (zh) 用于有效控制急性和/或慢性疼痛的药物及其施用方法
US11167005B2 (en) Peptides for treating Sjogren's syndrome
RU2025100211A (ru) Способы лечения ожирения агонистом mc4r
RU2022132255A (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
Pentel et al. Effects of high intravenous doses of dynorphin A (1–13) on tail flick latency and central nervous system histology in rats
US20160158322A1 (en) Ndp-msh for treatment of inflammatory and/or neurodegenerative disorders of the central nervous system
Scarpignato Octreotide, the Synthetic Long-Acting Somatostatin Analogue: Pharmacological
Wang Bremelanotide (Vyleesi): A Melanocortin Receptor Agonist for Treating Female Hypoactive Sexual Desire Disorder
HK40073416A (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US20200360484A1 (en) Ndp-msh for treatment of inflammatory and/or neurodegenerative disorders of the cns
HK40046859A (en) Pharmaceutical compositions
HK1220702B (en) Pharmaceutical compositions
EP1941902A1 (en) Use of Somatostatin analogs in cluster headache